SCHEMBL1613696

SCHEMBL1613696

NCCC(C(=O)O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.56
CYP2C19 P33261 1/20 0.53
EPHX1 P07099 1/20 0.48
HTR2A P28223 1/20 0.47
CYP2D6 P10635 1/20 0.46
SRC P12931 1/20 0.46
GABBR2 O75899 1/20 0.46
GABBR1 Q9UBS5 1/20 0.46
LMNA P02545 2/20 0.45
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.45
ROCK2 O75116 1/20 0.45
TBXAS1 P24557 1/20 0.44
CPN1 P15169 1/20 0.43
CPB2 Q96IY4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27843751 0.98 HRH1 (0.54) HRH1CYP2C19EPHX1HTR2ACYP2D6
Hydrochloric Acid SCHEMBL1093394 0.98 HRH1 (0.54) HRH1CYP2C19EPHX1HTR2ACYP2D6
SCHEMBL3781893 0.88 HRH1 (0.59) HRH1CYP2C19EPHX1HTR2ACYP2D6
SCHEMBL11115550 0.88 HRH1 (0.56) HRH1CYP2C19EPHX1HTR2ACYP2D6
SCHEMBL30371912 0.87 CYP2C19 (0.61) CYP2C19EPHX1CYP2D6SRCLMNA
SCHEMBL5322781 0.86 HRH1 (0.52) HRH1CYP2C19EPHX1HTR2ATBXAS1
SCHEMBL27691659 0.86 EPHX1 (0.61) HRH1CYP2C19EPHX1HTR2ACYP2D6
SCHEMBL11502865 0.86 HRH1 (0.54) HRH1CYP2C19EPHX1HTR2ACYP2D6
SCHEMBL20850639 0.85 TBXAS1 (0.54) HRH1CYP2C19EPHX1HTR2ATBXAS1
SCHEMBL12824732 0.84 HRH1 (0.52) HRH1CYP2C19EPHX1HTR2AGABBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114432423-A NF for treating diseases and disorderskInhibitors of B activity 拉金德拉·萨哈伊·巴特纳格尔 2022-05-06 CN claimed
EP-3197474-A2 INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS Bhatnagar, Rajendra, Sahai (US) 2017-08-02 EP claimed
WO-2016049580-A2 INHIBITORS OF NF KAPPA-B ACTIVITY FOR TREATMENT OF DISEASES AND DISORDERS BHATNAGAR RAJENDRA SAHAI (US) 2016-03-31 WO claimed
CN-103547240-B For the autonomic balance of the mankind and the system and method maintaining health SOLACE LIFESCIENCES, INC. (US) 2016-03-30 CN claimed
CN-103547240-A Systems and methods for balancing and maintaining the health of the human autonomic nervous system SOLACE LIFESCIENCES INC 2014-01-29 CN claimed
CN-102282144-A Oxadiazole derivatives as sphingosine-1-phosphate 1 receptor agonists 2011-12-14 CN claimed
US-7309719-B1 Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid WARNER LAMBERT COMPANY, LLC (US) 2007-12-18 US claimed
CN-1303991-C Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivative process for preparing the same WARNER LAMBERT CO (US) 2007-03-14 CN claimed
EP-1174151-B1 THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT DAIICHI ASUBIO PHARMA CO LTD (JP) 2007-01-24 EP claimed
CN-1206212-C Tri-substd. phenyl derivs. and analogues ASTRAZENECA AB (SE) 2005-06-15 CN claimed
EP-1077692-B1 AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME WARNER LAMBERT CO (US) 2004-07-28 EP claimed
US-6677344-B2 Chymase inhibitor for the treatment of eosinophilia DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-01-13 US claimed
US-6500835-B2 FOR PROPHYLAXIS AND THERAPY OF FIBROSIS INVOLVING EXTRACELLULAR MATRIX DYSBOLISM HAVING A CHYMASE INHIBITOR AS AN EFFECTIVE INGREDIENT; SIDE EFFECT REDUCTION SUNTORY LIMITED (JP) 2002-12-31 US claimed
CN-1301155-A Stable pharmaceutical formulation of gamma-aminobutyric acid derivatives and process for preparing the same WARNER LAMBERT CO (US) 2001-06-27 CN claimed
WO-1996011680-A2 USE OF GABA AGONISTS IN THE TREATMENT OF EMESIS GLAXO GROUP LIMITED (GB) 1996-04-25 WO claimed
EP-0025846-B1 IMPROVED PROCESS FOR THE PREPARATION OF VINYLCYCLOPROPANE DERIVATIVES NATIONAL DISTILLERS AND CHEMICAL CORPORATION (US) 1984-03-07 EP claimed
US-20250302803-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES UNIVERSITY OF HOUSTON SYSTEM (US) 2025-10-02 US disclosed
US-12357610-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures UNIVERSITY OF HOUSTON SYSTEM (US) 2025-07-15 US disclosed
US-4158733-A 7β-Acyloxy-3-acetoxymethyl cephalosporins SMITHKLINE CORPORATION (US) 1979-06-19 US disclosed
US-4144232-A Substituted azetidin-2-one antibiotics ELI LILLY AND COMPANY (US) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12357610-B2 Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures AADAC, GABRB2, GABARAPL2 HRH1 1750/4885CYP2C19 148/4885EPHX1 1151/4885
US-20250302803-A1 ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES AADAC, GABRB2, GABARAPL2 HRH1 1750/4885CYP2C19 148/4885EPHX1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.